Wall Street brokerages expect that Genmab A/S (NASDAQ:GMAB) will report $411.00 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Genmab A/S’s earnings, with the highest sales estimate coming in at $416.55 million and the lowest estimate coming in at $405.44 million. The firm is expected […]
